One-liner#

Gout management requires treating acute flares (NSAIDs, colchicine, or steroids), initiating urate-lowering therapy (ULT) when indicated with prophylaxis, and targeting serum uric acid <6 mg/dL to prevent recurrent attacks and tophi.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

Clinical diagnosis of gout (ACR/EULAR 2015 criteria):

• Monosodium urate (MSU) crystal identification in synovial fluid or tophus is the gold standard
• Clinical diagnosis acceptable when classic presentation and response to therapy

Classic clinical features supporting diagnosis:

• Acute onset of severe joint pain, swelling, erythema reaching maximum within 6-12 hours
• First MTP joint involvement (podagra) - present in 50% of first attacks, 90% lifetime
• Monoarticular involvement (especially lower extremity)
• Complete resolution between attacks (early disease)
• Elevated serum uric acid (though may be normal during acute attack)

ACR/EULAR classification criteria (for research; score ≥8 = gout):

• Entry criterion: at least one episode of swelling, pain, or tenderness in peripheral joint/bursa
• Sufficient criterion: MSU crystals in symptomatic joint or tophus (diagnostic)
• Clinical domains: pattern of involvement, characteristics, time course, tophi, serum urate, imaging

Epidemiology#

Gout affects approximately 4% of US adults (9.2 million people), making it the most common inflammatory arthritis. Male predominance 3:1 (equalizes after menopause). Peak incidence: men 40-50 years, women post-menopause. Risk factors: hyperuricemia, obesity, hypertension, CKD, diuretic use, high-purine diet, alcohol (especially beer), fructose-sweetened beverages. Prevalence increasing due to obesity epidemic and aging population.

Pathophysiology#

Mechanism (clinical understanding)#

Hyperuricemia and crystal formation: Uric acid is the end product of purine metabolism. Humans lack uricase (present in other mammals), so we cannot break down uric acid further. When serum uric acid exceeds its solubility threshold (~6.8 mg/dL), monosodium urate (MSU) crystals can form and deposit in joints and soft tissues.

Why crystals cause inflammation: MSU crystals are recognized by the innate immune system as danger signals. They activate the NLRP3 inflammasome in macrophages, triggering IL-1β release and intense neutrophilic inflammation. This explains the dramatic inflammatory response of acute gout.

Factors affecting uric acid levels:

• Overproduction (10%): High-purine diet, cell turnover (malignancy, psoriasis), genetic enzyme defects
• Underexcretion (90%): CKD, diuretics, low-dose aspirin, cyclosporine, alcohol, metabolic syndrome

Why ULT works: Lowering serum uric acid below 6 mg/dL (below saturation point) allows existing crystals to dissolve over time. This prevents new crystal formation and gradually depletes tissue crystal burden, reducing flare frequency and preventing tophi.

How to explain to patients#

Gout happens when a waste product called uric acid builds up in your blood and forms tiny crystals in your joints. These crystals cause sudden, severe pain and swelling.

Think of it like salt dissolving in water. If you add too much salt, it starts to form crystals at the bottom. The same thing happens with uric acid in your body when levels get too high.

The good news is we can lower your uric acid levels with medication. Over time, this dissolves the crystals and prevents future attacks. It takes months to years to fully clear the crystals, which is why you need to take the medication long-term.

Clinical presentation#

Characteristic symptoms#

Acute gout flare:

• Rapid onset (often overnight) of severe joint pain
• Maximum intensity within 6-12 hours
• Affected joint is swollen, red, warm, and exquisitely tender
• Pain so severe that even bedsheet contact is intolerable
• May have low-grade fever, malaise

Classic locations (in order of frequency):

• First MTP joint (podagra) - most common
• Ankle, midfoot
• Knee
• Wrist, fingers
• Elbow (olecranon bursa)

Intercritical gout:

• Asymptomatic periods between flares
• Early disease: complete resolution, months to years between attacks
• Progressive disease: shorter intervals, incomplete resolution, polyarticular involvement

Chronic tophaceous gout:

• Visible tophi (chalky deposits) in soft tissues
• Common sites: ears, olecranon, fingers, Achilles tendon
• Chronic joint damage and deformity
• Indicates years of inadequately treated hyperuricemia

Physical exam findings#

During acute flare:

• Intense erythema, warmth, swelling of affected joint
• Exquisite tenderness (patient guards joint)
• May have overlying skin desquamation as flare resolves
• Limited range of motion due to pain

Chronic gout:

• Tophi: firm, whitish nodules; may ulcerate and drain chalky material
• Joint deformity (late finding)
• Skin changes over tophi

Associated findings:

• Obesity (common comorbidity)
• Signs of metabolic syndrome
• Hypertension

Red flags#

• Fever >101°F with monoarticular swelling: Must rule out septic arthritis
• Immunocompromised patient with joint swelling: Higher risk of septic arthritis
• Prosthetic joint involvement: Requires urgent orthopedic evaluation
• First attack in young patient (<25 years): Consider secondary causes, genetic disorders
• Polyarticular presentation on first attack: Consider other diagnoses
• Failure to respond to appropriate therapy within 48-72 hours: Reconsider diagnosis

Diagnostic workup#

Initial evaluation#

Clinical assessment:

• History: prior attacks, location, timing, triggers, medications (diuretics, aspirin)
• Family history of gout
• Diet and alcohol intake
• Comorbidities: CKD, HTN, diabetes, CVD

Laboratory studies:

• Serum uric acid: Elevated in most patients, but may be normal or low during acute attack (cytokine-mediated uricosuria)
• CBC: Leukocytosis common during flare
• BMP: Assess renal function (affects treatment choices)
• Lipid panel, glucose/A1c: Screen for metabolic syndrome

When to aspirate (gold standard):

• First attack (to confirm diagnosis and rule out septic arthritis)
• Atypical presentation
• Concern for infection
• Diagnostic uncertainty

Confirmatory testing#

Synovial fluid analysis (definitive diagnosis):

• MSU crystals: Needle-shaped, negatively birefringent under polarized microscopy
• Cell count: Typically 10,000-70,000 WBC/mm³, neutrophil predominant
• Gram stain and culture: To rule out septic arthritis (can coexist with gout)

Imaging (not required for typical presentation):

• X-ray: Normal early; late findings include “punched-out” erosions with overhanging edges, preserved joint space
• Ultrasound: “Double contour sign” (urate deposition on cartilage surface), tophi
• Dual-energy CT: Highly sensitive for urate deposits; useful for atypical cases or tophus confirmation

When to refer for specialist workup#

• Diagnostic uncertainty after initial evaluation
• Suspected septic arthritis (urgent)
• Refractory gout despite appropriate ULT
• Severe tophaceous gout
• Gout with advanced CKD (eGFR <30)
• Young patient (<25 years) with gout
• Suspected secondary cause of hyperuricemia

What NOT to order#

• Serum uric acid alone to diagnose acute gout: Can be normal during flare; clinical picture matters more
• Routine imaging for typical presentation: Clinical diagnosis is sufficient
• 24-hour urine uric acid routinely: Only if considering uricosuric therapy or evaluating overproduction
• Dual-energy CT for routine cases: Reserve for diagnostic uncertainty or research

Treatment#

Goals of therapy#

Acute flare:

• Rapid pain relief (within 24-48 hours)
• Resolution of inflammation

Long-term management:

• Serum uric acid target: <6 mg/dL (or <5 mg/dL if tophi present)
• Prevent recurrent flares
• Dissolve existing crystal deposits and tophi
• Prevent joint damage

Non-pharmacologic management#

Pharmacologic management#

Acute flare treatment (choose one based on patient factors):

Urate-lowering therapy (ULT):

Flare prophylaxis during ULT initiation:

Patient counseling points#

For acute flare treatment:

• “Start treatment as soon as you feel a flare coming on. The earlier you treat, the faster it resolves.”
• “Rest the joint and apply ice for 20 minutes several times a day.”
• “The flare should improve significantly within 24-48 hours. If not, call us.”

For starting ULT:

• “This medication lowers your uric acid over time. It does NOT treat acute flares.”
• “You may actually have more flares when starting this medication. That’s normal and expected as crystals dissolve.”
• “Take the prophylaxis medication (colchicine) to prevent flares while we adjust your dose.”
• “This is a long-term medication. Stopping it will cause your uric acid to rise and flares to return.”

For lifestyle changes:

• “Diet changes alone rarely control gout, but they help. Limit beer, organ meats, and sugary drinks.”
• “Losing weight and staying hydrated are the most impactful lifestyle changes.”

Monitoring and follow-up#

Patient education#

What is this condition?#

Gout is a type of arthritis caused by too much uric acid in your blood. Uric acid is a normal waste product, but when levels get too high, it forms tiny crystals that collect in your joints.

These crystals cause sudden attacks of severe pain, swelling, and redness, usually in one joint at a time. The big toe is the most common spot, but gout can affect ankles, knees, wrists, and other joints.

Gout tends to run in families and is more common in men. It is also linked to being overweight, high blood pressure, kidney problems, and certain medications.

What you can do#

During a flare, rest the joint and apply ice wrapped in a towel for 20 minutes at a time. Take your flare medication as soon as symptoms start.

Drink plenty of water every day to help your body get rid of uric acid. Aim for 8-10 glasses daily.

Limit foods high in purines like organ meats, shellfish, and red meat. Cut back on beer and sugary drinks.

Lose weight if you are overweight. Even a small amount of weight loss can lower your uric acid.

Take your uric acid-lowering medication every day, even when you feel fine. This prevents future attacks.

When to seek care#

Call your doctor if you have a gout flare that does not improve within 48 hours of starting treatment.

Call your doctor if you develop fever with joint swelling, as this could be an infection.

Call your doctor if you have frequent flares despite taking your medication.

Go to urgent care or the ER if you have severe joint pain with high fever or if you cannot bear weight on the affected joint.

Questions to ask your doctor#

What is my uric acid level, and what should it be?

Should I be on medication to prevent future attacks?

Are any of my current medications making my gout worse?

How long do I need to take the preventive medication?

Prognosis and monitoring#

Expected course#

Without treatment:

• Flares become more frequent and severe over time
• Intercritical periods shorten
• Polyarticular involvement develops
• Tophi form after years of hyperuricemia
• Joint damage and chronic arthritis

With appropriate ULT:

• Flare frequency decreases over 6-12 months
• Tophi shrink and may resolve over 1-2 years
• Joint damage prevented if treated before chronic changes
• Most patients achieve excellent control with adherence

Timeline for ULT benefits:

• Uric acid target reached: 2-6 months (with proper titration)
• Flare frequency reduction: 6-12 months
• Tophus resolution: 1-3 years
• Crystal dissolution: ongoing over years

Monitoring parameters#

Complications to watch for#

From gout itself:

• Chronic tophaceous gout with joint destruction
• Nephrolithiasis (uric acid stones)
• Chronic kidney disease (urate nephropathy)
• Increased cardiovascular risk

From medications:

• Allopurinol hypersensitivity syndrome (rare but serious): fever, rash, eosinophilia, organ involvement
• NSAID complications: GI bleeding, renal impairment, cardiovascular events
• Colchicine toxicity: diarrhea, myopathy (especially with CKD or drug interactions)

Special populations#

Elderly/geriatric#

Diagnosis considerations:

• Atypical presentations more common (polyarticular, upper extremity)
• May present with low-grade symptoms
• Higher prevalence due to CKD and diuretic use

Treatment considerations:

• NSAIDs: Avoid or use with extreme caution (GI, renal, CV risks)
• Colchicine: Reduce dose; higher toxicity risk; avoid with CKD
• Prednisone: Often safest option for acute flares in elderly
• Allopurinol: Start at 50-100 mg; titrate slowly; adjust for renal function

Beers criteria:

• NSAIDs: Avoid in patients >75 or with CKD, heart failure, or GI risk
• Colchicine: Use with caution; reduce dose in renal impairment
• Indomethacin: Specifically avoid (highest CNS and GI risk among NSAIDs)

Chronic kidney disease#

Diagnosis:

• CKD is both a cause and consequence of gout
• Hyperuricemia common in CKD due to decreased uric acid excretion

Treatment adjustments:

Polypharmacy considerations:

• Review for drugs causing hyperuricemia: thiazides, loop diuretics, low-dose aspirin, cyclosporine
• Colchicine interactions: statins (myopathy risk), P-gp inhibitors, CYP3A4 inhibitors
• Consider switching thiazide to losartan (has uricosuric effect)

Other populations#

Cardiovascular disease:

• Gout associated with increased CV risk
• Avoid NSAIDs if possible (CV events)
• Febuxostat: FDA warning about CV mortality (CARES trial); use allopurinol first-line
• Treat gout aggressively; hyperuricemia may contribute to CV risk

Organ transplant recipients:

• High gout prevalence due to cyclosporine, diuretics
• Colchicine: Reduce dose significantly; dangerous interactions with cyclosporine
• Allopurinol: Interacts with azathioprine (reduce azathioprine dose by 50-75%)
• Febuxostat: Fewer drug interactions; may be preferred

Diabetes:

• Gout and diabetes commonly coexist (metabolic syndrome)
• Steroids: Monitor glucose closely; may need insulin adjustment
• SGLT2 inhibitors: Have uricosuric effect; may help both conditions

When to refer#

Specialist referral criteria#

Urgency levels#

Smartphrase snippets#

Acute gout flare: Acute gout flare of [joint]. Started [NSAID/colchicine/prednisone] with improvement. Counseled on ice, rest, and early treatment of future flares.

Starting ULT: Gout with [X] flares in past year. Starting allopurinol 100 mg daily with colchicine prophylaxis. Target uric acid <6 mg/dL; recheck in 2-4 weeks to titrate.

ULT maintenance: Gout on allopurinol [dose] with uric acid [X] mg/dL at goal. No flares in [X] months. Continue current regimen; annual monitoring.

Related pages#

• Monoarticular Swelling (complaint) — acute gout is a common cause of monoarticular swelling
• Polyarthralgia (complaint) — chronic polyarticular gout in differential
• Foot Pain (complaint) — podagra (first MTP gout) is common cause
• Knee Pain (complaint) — gout can affect the knee
• Osteoarthritis (problem) — gout and OA commonly coexist; both cause joint pain
• Chronic Kidney Disease (problem) — CKD causes hyperuricemia; gout can worsen CKD
• Hypertension (problem) — diuretics cause hyperuricemia; losartan has uricosuric effect